Clinical Trial Update: Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating thalidomide in patients with recurrent or persistent endometrial cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Adenoacanthoma
• Endometrial Adenocarcinoma
• Endometrial Adenosquamous Carcinoma
• Endometrial Carcinoma
• Endometrial Clear Cell Carcinoma
• Endometrial Papillary Serous Carcinoma

Drugs mentioned

• Thalidomide (thalidomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Endometrial Adenoacanthoma, Endometrial Adenocarcinoma | Phase 2 | Status: COMPLETED